Clinical Trial Update: Cemiplimab and Cetuximab Prior Salvage Surgery in Patients With Recurrent Oral Cavity Squamous Cell Carcinoma (OCSCC). [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating cemiplimab and cetuximab as prior salvage therapy before surgery for locally recurrent oral cavity squamous cell carcinoma. Th…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Oral Cavity Squamous Cell Carcinoma

Drugs mentioned

• ERBITUX (cetuximab)
• Libtayo (cemiplimab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Locally Recurrent Oral Cavity Squamous Cell Carcinoma | Phase 2 | Status: RECRUITING